Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib
Warburg metabolism
breast cancer
metabolic reprogramming
palbociclib
resistance
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
10 03 2020
10 03 2020
Historique:
received:
11
02
2020
revised:
02
03
2020
accepted:
06
03
2020
entrez:
14
3
2020
pubmed:
14
3
2020
medline:
11
3
2021
Statut:
epublish
Résumé
The majority of breast cancers express the estrogen receptor (ER) and are dependent on estrogen for their growth and survival. Endocrine therapy (ET) is the standard of care for these tumors. However, a superior outcome is achieved in a subset of ER positive (ER
Identifiants
pubmed: 32164162
pii: cells9030668
doi: 10.3390/cells9030668
pmc: PMC7140692
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Piperazines
0
Pyridines
0
palbociclib
G9ZF61LE7G
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
NPJ Breast Cancer. 2018 Nov 28;4:38
pubmed: 30511015
N Engl J Med. 2015 Oct 22;373(17):1672-3
pubmed: 26488700
Mol Cell. 2017 Oct 19;68(2):336-349.e6
pubmed: 29053957
Breast Care (Basel). 2017 Oct;12(5):304-308
pubmed: 29234249
Lancet Oncol. 2015 Jan;16(1):25-35
pubmed: 25524798
PLoS One. 2012;7(12):e51862
pubmed: 23251644
Cell Rep. 2016 Feb 9;14(5):979-990
pubmed: 26804906
Mol Metab. 2020 Mar;33:48-66
pubmed: 31395464
PLoS One. 2011;6(12):e28536
pubmed: 22194845
Cancer Res. 2016 Apr 15;76(8):2301-13
pubmed: 27020857
Nature. 2014 Jun 26;510(7506):547-51
pubmed: 24870244
Cancer Res. 2011 Jul 1;71(13):4585-97
pubmed: 21498634
Cancer Cell. 2016 Mar 14;29(3):255-269
pubmed: 26977878
Cancer Res. 2017 May 1;77(9):2488-2499
pubmed: 28249908
J Exp Clin Cancer Res. 2018 Mar 27;37(1):72
pubmed: 29587820
J Cell Physiol. 2019 Feb;234(2):1768-1779
pubmed: 30132876
Anal Chem. 2009 Dec 15;81(24):10038-48
pubmed: 19928838
Cells. 2019 Apr 06;8(4):
pubmed: 30959874
Front Oncol. 2019 Jul 23;9:666
pubmed: 31396487
N Engl J Med. 2016 Nov 3;375(18):1738-1748
pubmed: 27717303
Cell Chem Biol. 2018 Mar 15;25(3):291-300.e3
pubmed: 29337187
J Clin Oncol. 2017 Nov 10;35(32):3638-3646
pubmed: 28968163
J Exp Med. 2011 Feb 14;208(2):313-26
pubmed: 21242296
Trends Biochem Sci. 2016 Mar;41(3):211-218
pubmed: 26778478
Cell Rep. 2019 Jul 2;28(1):104-118.e8
pubmed: 31269432
Breast Cancer Res Treat. 2016 Dec;160(3):439-446
pubmed: 27744485
Nat Commun. 2017 Jun 27;8:15916
pubmed: 28653662
Oncogene. 2009 Oct 22;28(42):3689-701
pubmed: 19668225
Crit Rev Oncol Hematol. 2017 Apr;112:208-214
pubmed: 28325261
Nature. 2017 Jun 15;546(7658):426-430
pubmed: 28607489
Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):1-6
pubmed: 28065746
Curr Opin Oncol. 2012 Nov;24(6):650-4
pubmed: 22913968
Cancer Res. 2016 Mar 15;76(6):1615-26
pubmed: 26795347
Int J Cancer. 2019 Sep 1;145(5):1179-1188
pubmed: 30478914
Cell Rep. 2018 Dec 11;25(11):3047-3058.e4
pubmed: 30540938
Science. 1956 Feb 24;123(3191):309-14
pubmed: 13298683